National research programme Precision psychiatry (PEPR PROPSY)
Launched on July 18, 2022, PROPSY research program is led by Inserm and CNRS, with support from the Fondation FondaMental. It has a budget of €80 million over 7 years allocated as part of the France 2030 investment plan. The scientific director is Professor Marion Leboyer and ANR is the operator on behalf of the French government. Thirteen targeted projects have been selected for funding. They are supplemented by calls for projects operated by ANR or Inserm.
|
Psychiatric pathologies are chronic and frequent, starting early in life and accounting for 5 of the 10 leading causes of disabilitý. In addition to their psychosocial impact, they reduce life expectancy by 15 to 20 years, due to somatic comorbidities and the risk of suicide. The total cost is estimated at 160 billion euros in France, positioning psychiatric pathologies as a major issue for the 21st century.
Yet, despite this major challenge, funding for psychiatric research in France represents only 2% to 4% of the biomedical research budget, one of the lowest levels in Europe.
The aim of the PEPR PROPSY program (exploratory research program in precision psychiatry) is to provide concrete solutions for the deployment of precision medicine in psychiatry, with a particular focus on 4 of the most disabling disorders: bipolar disorders, resistant depression, schizophrenia and autism spectrum disorders.
The main objectives of the program are :
- Improve diagnosis and treatment, by identifying homogeneous patient subgroups to develop personalized approaches.
- Strengthen research and innovation in psychiatry, by structuring a biomedical sector dedicated to psychiatric illnesses,
- Attract and train new talent, by making mental health-related professions more attractive.